Fulgent Genetics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $322.7 | $283.5 | $289.2 | $619.0 | $992.6 |
| Operating income | -$91.1 | -$73.9 | -$195.5 | $178.5 | $676.0 |
| Net income | -$60.5 | -$42.7 | -$167.8 | $143.4 | $507.4 |
| Cash Flow Statement | |||||
| Free cash flow | -$124.2 | -$19.3 | $4.8 | $234.7 | $514.8 |
| Share repurchases | $10.9 | $0.2 | $25.1 | $74.3 | — |
Shares outstanding 27.5M · Free float 22.9%
Annual filing data through FY ended December 31, 2025; float as of September 12, 2026.